Elson Yong, Carecam - AI-Powered Solutions to Identify Gait Disorders | LSI USA '24

Elson Yong  0:03  
My name is Elson. I am the CEO and co founder of CAD CAM. Essentially CAD CAM is a digital health company. What we do is redefine therapeutics by using human body motion as digital biomarkers. We are in the business of movement disorder management. Let me give you a general brief of what movement disorders are they are your increase or slow movement that are either voluntary or involuntary. They're commonly present in cardiovascular or neurological diseases, for example, in a Parkinson's disease or in patients suffering from stroke. So, we believe that using human motion as a biomarker helps clinicians to drive diagnosis, prognosis and even monitoring the patient's recovery. The use of body human body motion as biomarkers has been around for the last 30 years, but we've seen them being uptake increase besides the clinical research, but also in the standard of care. They're mainly driven by the three markets and frailty in neurological and in the musculoskeletal verticals. It has a combined market cap of about $52 billion and growing at a 6.7% Kaggle. We look around the market what is the current what we call a gold standard, the current clinical system for measuring human body motion right now it requires your patients to put on bodysuits require patients to put on notes sensors. By the way, the guy on the left is actually me putting on the notes it took me four hours to actually put it up. All this in the clinical setting is a fixed asset with more than six cameras system as big as the seminar room. And it costs hospitals at upwards of a million dollars. So clearly hospitals or clinics are not equipped to fork out these costs. So what we have derived is a proprietary solution which we're going to show in the video, I hope you enjoy it. Right, if you're already excited about our flagship product treaty gate is essentially a AI powered platform that measures and analyze human motion is a simple four step progress, you just need to open the mobile app in the iPad Pro, take a video recording of a patient walking with the stage of a length of the stage, you will be able to generate about 48 Digital biomarkers in less than 10 minutes. And it gives us actually actionable data insights to inform therapeutics by the cardiologist or the neurologist or what kind of intervention they have given. So why we are special we have actually more than 2 million proprietary motion capture data that we use as a baseline. And we've benchmark this against what we call the gold standard with digital biomarkers with high accuracy. Our margin of error for the Angra Angular biomarkers are three degrees of spatial biomarkers about three centimeters for temporal about 0.1 seconds. All these can be done by working closely with our clinical partners and with our proprietary AI technology. So at the moment, we have already won us granted Peyton and four of them are drafting in progress. So we have achieved so much in Asia. Because of our strong partnership with our clinical partners. based in Singapore, we have three healthcare clusters is working together with us, your largest hospital groups in Singapore. We are also supported by commercial partners in Apple AWS plug and play. We're interested in the digital health side of things. We are also supported by some of the government partners and by the Singapore and also our regulatory partners that help us to drive the FDA submission. The one of the success stories I like to tell with with the audience's with the collaboration with the National Heart Center of Singapore So we have recruited over 200 Patients who suffer from cardiovascular disease. They're mainly patients over the age of 65. And we give them a control group of an intervention, either from diet food nutrition, or physiotherapy. What it essentially does is help the cardiologists to monitor the effectiveness of the therapeutics has been given using human motion, and also associate their current cardiac data with human motion that will actually lead to new digital biomarkers that we have created. We have exciting things happening in the next three years, our product plan of 3d gait because it's so flexible as a clinical research tool, it can be used as a support tool for home recovery. We're working with Apple Health with that pre surgical planning, heat stroke prediction. But at the same time, we want to focus on being driven as a medical device. We'll be working with cardiologists and cardio aging cases, or neurologists for stroke and Parkinson's. So at the moment, we are actually falling for FDA submission. We are going to be FDA FDA class two 510 K by q3 this year. We are fairly limited budget we have a build a strong team of technologies, clinicians and commercial partners, we hope based in Singapore and the US. Some of our key advisors are based in the University of South Dakota Sanford Health, VA hospitals. Right now we are raising our capital needs. For us go to market strategy, we are raising us 2 million. We are going to attain three with b2b customers and 1000 research users. We're going to secure one hospital groups that utilize the existing CPT codes reimbursement codes, and not to forget to deepen our product and clinical development for existing and new diseases. Well, in conclusion, CAD CAM is uniquely positioned to use human motion as digital biomarkers to enable early interventions and deliver personalized care to patients. We have a patented technology and trade secrets with more than 2 million proprietary data sets. 3d Gate is our flagship product is it accessible quantitative and inexpensive clinical research used to but at the same time, we are moving towards the software as a medical device from at the moment we are raising 2 million for 24 months of runway. So those who are excited what we've seen, you can scan a QR code register for insurance for our flagship product. You can register for interest less than 60 seconds and we can give a discounted rate for any b2b Customers they're working. If you like we can show you a live demo or be at the back of the stage and show you what we have done. If your investors who are interested to help us bring this technology to this part of the world, you can contact me I'm happy to drink coffee, and I'll be happy to be around this couple of days. Thank you